We evaluated demographic characteristics and graft composition as risk factors for acute graft-versus-host disease (GVHD) in 160 adult recipients of HLA-identical allogeneic blood stem cell transplants. The patients received a median nucleated cell dose of 7.9 3 108/kg and median C341 cell dose of 5.6 3 106/kg. GVHD prophylaxis consisted of cyclosporine (CSA) and steroids, tacrolimus (FK506) an...

Although graft-versus-host disease (GVHD) is a life-threatening complication of hematopoietic stem-cell transplantation (HSCT), its current diagnosis depends mainly on clinical manifestations and invasive biopsies. Specific biomarkers for GVHD would facilitate early and accurate recognition of this grave condition. Using proteomics, we screened for plasma proteins specific for GVHD in a mouse m...

This study was conducted to elucidate the influence of immunosuppressive treatment (IST) and GVHD on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation (HCT). The study cohort included 2656 patients who received allogeneic HCT after high-intensity conditioning regimens for treatment of hematologic malignancies. Rates and hazard ratios of relapse and mortality were ...

Allogeneic hematopoietic cell transplantation (HCT) is a well-established therapeutic modality effective for a variety of hematological malignancies but, unfortunately, is associated with significant morbidity and mortality related to cancer relapse as well as to transplant-related complications including graft-versus-host-disease (GvHD). Natural killer (NK) cells are the first donor-derived ly...

Abstract We were the first to demonstrate that targeting JAK1/2 using baricitinib (BARI) and ruxolitinib (RUX) prevents treats GVHD while enhancing multi-lineage hematopoietic reconstitution graft-vs-leukemia (GvL) effect in mouse models of allogeneic cell transplantation (allo-HCT). However, unlike BARI, RUX fails completely prevent or treat GvHD. To elucidate mechanism underlying superiority ...

Treatment of acute graft-versus-host disease (GVHD) has evolved from a one-size-fits-all approach to a more nuanced strategy based on predicted outcomes. Lower and time-limited doses of immune suppression for patients predicted to have low-risk GVHD are safe and effective. In more severe GVHD, prolonged exposure to immunosuppressive therapies, failure to achieve tolerance, and inadequate clinic...

GVHD: graft-versus-host-disease INTRODUCTION Acute graft-versus-host disease (GVHD) is the major complication of hematopoietic cell transplantation and affects multiple organs and systems, most commonly the skin. We report a case of acute GVHD localized to a tattoo in a patient with a history of allogeneic hematopoietic cell transplantation and describe typical and atypical cutaneous findings i...

Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow transplantation. GVHD is caused by donor T cells that recognize and react to recipient histocompatibility differences, resulting in significant morbidity and mortality. The pathophysiology of GVHD is complex, which occurs in three phases: induction phase, activation phase and effector phase. Numerous studies have...

INTRODUCTION The transplantation of hematopoietic stem cells (HSCT) is a therapeutic intervention where the hematopoietic stem cells and the cells originating from them are being removed and replaced by the normal stem cells of donor or the patient him/her-self. HSCT today represent standardized biological manipulation for treating malignant, genetic and autoimmune diseases. The application of ...

Abstract It has been observed that a constriction of the gut microbiome occurs with high fat diet, and likewise decreased diversity is directly correlated more severe graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation. Taken together it plausible not only content, but source dietary could influence microbiota GvHD outcome. We sought to address this que...